Patents by Inventor Staci Sabnis
Staci Sabnis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11969506Abstract: The disclosure features novel lipids and compositions involving the same. Nanoparticle compositions include an ionizable lipid, a phospholipid, a first sterol or a tocopherol, and optionally a second sterol different from the first sterol. Nanoparticle compositions further including therapeutic and/or prophylactics such as RNA are useful in the delivery of therapeutic and/or prophylactics to mammalian cells or organs to, for example, regulate polypeptide, protein, or gene expression.Type: GrantFiled: March 15, 2018Date of Patent: April 30, 2024Assignees: ModernaTX, Inc., Oregon State UniversityInventors: Siddharth Patel, Emily Robinson, Anna Brown, Orn Almarsson, Kerry E. Benenato, Staci Sabnis, Gaurav Sahay, Ashwani Kumar Narayana
-
Publication number: 20230323371Abstract: The invention relates to mRNA therapy for the treatment of Fabry disease. mRNAs for use in the invention, when administered in vivo, encode human the ?-galactosidase A (GLA), isoforms thereof, functional fragments thereof, and fusion proteins comprising GLA. mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to effect efficient delivery to cells and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of GLA expression and/or activity in subjects. mRNA therapies of the invention further decrease levels of toxic metabolites associated with deficient GLA activity in subjects, namely Gb3 and lyso-Gb3.Type: ApplicationFiled: April 6, 2023Publication date: October 12, 2023Inventors: Paolo MARTINI, Stephen G. HOGE, Kerry BENENATO, Vladimir PRESNYAK, Iain MCFADYEN, Ellalahewage Sathyajith KUMARASINGHE, Xuling ZHU, Lin Tung GUEY, Staci SABNIS
-
Publication number: 20230233475Abstract: This disclosure relates to ionizable lipid-based lipid nanoparticles for delivery of mRNA encoding glucose-6-phosphatase. Lipid nanoparticle/mRNA therapies of the invention increase and/or restore deficient levels of glucose-6-phosphatase expression and activity in subjects and are useful for the treatment of glycogen storage disease type 1a (GSD-Ia). Lipid nanoparticle/mRNA therapies of the invention increase glucose production and reduce the abnormal accumulation of glycogen and glucose-6-phosphate associated with GSD-Ia.Type: ApplicationFiled: June 1, 2021Publication date: July 27, 2023Inventors: Kerry Benenato, Kristine Burke, Jingsong Cao, Paloma Hoban Giangrande, Edward J. Hennessy, Stephen Hoge, Jaclyn Milton, Staci Sabnis, Timothy Salerno, Matthew Theisen
-
Patent number: 11649461Abstract: The invention relates to mRNA therapy for the treatment of Fabry disease. mRNAs for use in the invention, when administered in vivo, encode human the ?-galactosidase A (GLA), isoforms thereof, functional fragments thereof, and fusion proteins comprising GLA. mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to effect efficient delivery to cells and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of GLA expression and/or activity in subjects. mRNA therapies of the invention further decrease levels of toxic metabolites associated with deficient GLA activity in subjects, namely Gb3 and lyso-Gb3.Type: GrantFiled: September 13, 2019Date of Patent: May 16, 2023Assignee: ModernaTX, Inc.Inventors: Paolo Martini, Stephen G. Hoge, Kerry Benenato, Vladimir Presnyak, Iain Mcfadyen, Ellalahewage Sathyajith Kumarasinghe, Xuling Zhu, Lin Tung Guey, Staci Sabnis
-
POLYNUCLEOTIDES ENCODING PORPHOBILINOGEN DEAMINASE FOR THE TREATMENT OF ACUTE INTERMITTENT PORPHYRIA
Publication number: 20230112986Abstract: The invention relates to mRNA therapy for the treatment of Acute Intermittent Porphyria (AIP). mRNAs for use in the invention, when administered in vivo, encode human porphobilinogen deaminase (PBGD), isoforms thereof, functional fragments thereof, and fusion proteins comprising PBGD. mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to affect efficient delivery to cells and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of PBGD expression and/or activity in subjects. mRNA therapies of the invention further decrease levels of toxic metabolites associated with deficient PBGD activity in subjects, namely porphobilinogen and aminolevulinate (PBG and ALA).Type: ApplicationFiled: July 21, 2022Publication date: April 13, 2023Applicants: ModernaTX, Inc., Fundacion Para La Investigacion Medica AplicadaInventors: Paolo MARTINI, Stephen HOGE, Kerry BENENATO, Vladimir PRESNVAK, Lei JIANG, Iain MCFADYEN, Ellalahewage Sathyajith KUMARASINGHE, Antonio FONTANELLAS ROMA, Pedro BERRAONDO LOPEZ, Matias Antonio AVILA ZARAGOZA, Lin Tung GUEY, Staci SABNIS -
Publication number: 20230027864Abstract: The disclosure features immune cell delivery lipid nanoparticle (LNP) compositions that allow for enhanced delivery of agents, e.g., nucleic acids, such as therapeutic and/or prophylactic RNAs, to immune cells, in particular T cells, as well as B cells, dendritic cells and monocytes. The LNPs comprise an effective amount of an immune cell delivery potentiating lipid such that delivery of an agent by an immune cell delivery LNP is enhanced as compared to an LNP lacking the immune cell delivery potentiating agent. Methods of using the immune cell delivery LNPs for delivery of agents, e.g., nucleic acid delivery, for protein expression, for modulating immune cell activity and modulating immune responses are also disclosed.Type: ApplicationFiled: May 18, 2022Publication date: January 26, 2023Inventors: Gilles BESIN, Luis BRITO, Stephen G. HOGE, Edward HENNESSY, Mark CORNEBISE, Kerry BENENATO, Staci SABNIS, Michael W. DANNEMAN
-
Publication number: 20220296517Abstract: The disclosure features target cell delivery lipid nanoparticle (LNP) compositions that allow for enhanced delivery of agents, e.g., nucleic acids, such as therapeutic and/or prophylactic RNAs, to target cells, in particular liver cells and/or splenic cells. The LNPs comprise an effective amount of a target cell delivery potentiating lipid such that delivery of an agent by a target cell target cell delivery LNP is enhanced as compared to an LNP lacking the target cell delivery potentiating agent. Methods of using the target cell target cell delivery LNPs for delivery of agents, e.g., nucleic acid delivery, for protein expression, and for modulating target cell activity are also disclosed.Type: ApplicationFiled: August 6, 2020Publication date: September 22, 2022Inventors: Kerry Benenato, Staci Sabnis, Edward Hennessy, Kristine Burke, Matthew Theisen, Jaclyn Milton, Timothy Salerno, Stephen Hoge
-
Publication number: 20220265857Abstract: This disclosure provides improved lipid-based compositions, including lipid nanoparticle compositions, and methods of use thereof for delivering agents in vivo including nucleic acids and proteins. These compositions are not subject to accelerated blood clearance and they have an improved toxicity profile in vivo.Type: ApplicationFiled: January 25, 2022Publication date: August 25, 2022Applicant: ModernaTX, Inc.Inventors: Gilles Besin, Stephen Hoge, Joseph Senn, Kerry Benenato, Staci Sabnis
-
Patent number: 11285222Abstract: This disclosure provides improved lipid-based compositions, including lipid nanoparticle compositions, and methods of use thereof for delivering agents in vivo including nucleic acids and proteins. These compositions are not subject to accelerated blood clearance and they have an improved toxicity profile in vivo.Type: GrantFiled: October 11, 2019Date of Patent: March 29, 2022Assignee: ModernaTX, Inc.Inventors: Gilles Besin, Stephen Hoge, Joseph Senn, Kerry Benenato, Staci Sabnis
-
Publication number: 20220071915Abstract: The invention relates to mRNA therapy for the treatment of Citrullinemia Type 2 (“CTLN2”). mRNAs for use in the invention, when administered in vivo, encode human Citrin, isoforms thereof, functional fragments thereof, and fusion proteins comprising Citrin. mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to effect efficient delivery to cells and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of Citrin expression and/or activity in subjects. mRNA therapies of the invention further decrease levels of biomarkers associated with deficient Citrin activity in subjects, namely ammonia and/or triglycerides.Type: ApplicationFiled: January 21, 2021Publication date: March 10, 2022Applicant: ModernaTX, Inc.Inventors: Paolo Martini, Stephen Hoge, Kerry Benenato, Vladimir Presnyak, Iain McFadyen, Ellalahewage Sathyajith Kumarasinghe, Jingsong Cao, Lin Tung Guey, Staci Sabnis
-
Publication number: 20210269830Abstract: The invention relates to mRNA therapy for the treatment of galactosemia type 1 (Gal-1). mRNAs for use in the invention, when administered in vivo, encode human galactose-1-phosphate uridylyltransferase (GALT), isoforms thereof, functional fragments thereof, and fusion proteins comprising GALT. mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to effect efficient delivery to cells and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of GALT expression and/or activity in subjects. mRNA therapies of the invention further decrease levels of toxic metabolites associated with deficient GALT activity in subjects, namely galactose-1-phosphate (Gal-1-P).Type: ApplicationFiled: January 21, 2021Publication date: September 2, 2021Applicant: ModernaTX, Inc.Inventors: Paolo Martini, Stephen Hoge, Kerry Benenato, Vladimir Presnyak, Iain McFadyen, Ellalahewage Sathyajith Kumarasinghe, Ding An, Staci Sabnis
-
Patent number: 11001861Abstract: The invention relates to mRNA therapy for the treatment of galactosemia type 1 (Gal-1). mRNAs for use in the invention, when administered in vivo, encode human galactose-1-phosphate uridylyltransferase (GALT), isoforms thereof, functional fragments thereof, and fusion proteins comprising GALT. mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to effect efficient delivery to cells and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of GALT expression and/or activity in subjects. mRNA therapies of the invention further decrease levels of toxic metabolites associated with deficient GALT activity in subjects, namely galactose-1-phosphate (Gal-1-P).Type: GrantFiled: May 18, 2017Date of Patent: May 11, 2021Assignee: ModernaTX, Inc.Inventors: Paolo Martini, Stephen Hoge, Kerry Benenato, Vladimir Presnyak, Iain McFadyen, Ellalahewage Sathyajith Kumarasinghe, Ding An, Staci Sabnis
-
Patent number: 10993918Abstract: The invention relates to mRNA therapy for the treatment of Citrullinemia Type 2 (“CTLN2”). mRNAs for use in the invention, when administered in vivo, encode human Citrin, isoforms thereof, functional fragments thereof, and fusion proteins comprising Citrin. mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to effect efficient delivery to cells and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of Citrin expression and/or activity in subjects. mRNA therapies of the invention further decrease levels of biomarkers associated with deficient Citrin activity in subjects, namely ammonia and/or triglycerides.Type: GrantFiled: May 18, 2017Date of Patent: May 4, 2021Assignee: ModernaTX, Inc.Inventors: Paolo Martini, Stephen Hoge, Kerry Benenato, Vladimir Presnyak, Iain McFadyen, Ellalahewage Sathyajith Kumarasinghe, Jingsong Cao, Lin Tung Guey, Staci Sabnis
-
Publication number: 20200206362Abstract: This disclosure provides improved lipid-based compositions, including lipid nanoparticle compositions, and methods of use thereof for delivering agents in vivo including nucleic acids and proteins. These compositions are not subject to accelerated blood clearance and they have an improved toxicity profile in vivo.Type: ApplicationFiled: October 11, 2019Publication date: July 2, 2020Applicant: Moderna TX, Inc.Inventors: Gilles Besin, Stephen Hoge, Joseph Senn, Kerry Benenato, Staci Sabnis
-
Publication number: 20200149052Abstract: The invention relates to mRNA therapy for the treatment of Fabry disease. mRNAs for use in the invention, when administered in vivo, encode human the ?-galactosidase A (GLA), isoforms thereof, functional fragments thereof, and fusion proteins comprising GLA. mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to effect efficient delivery to cells and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of GLA expression and/or activity in subjects. mRNA therapies of the invention further decrease levels of toxic metabolites associated with deficient GLA activity in subjects, namely Gb3 and lyso-Gb3.Type: ApplicationFiled: September 13, 2019Publication date: May 14, 2020Inventors: Paolo MARTINI, Stephen G. HOGE, Kerry BENENATO, Vladimir PRESNYAK, Iain MCFADYEN, Ellalahewage Sathyajith KUMARASINGHE, Xuling ZHU, Lin Tung GUEY, Staci SABNIS
-
Publication number: 20200129445Abstract: The disclosure features novel lipids and compositions involving the same. Nanoparticle compositions include an ionizable lipid, a phospholipid, a first sterol or a tocopherol, and optionally a second sterol different from the first sterol. Nanoparticle compositions further including therapeutic and/or prophylactics such as RNA are useful in the delivery of therapeutic and/or prophylactics to mammalian cells or organs to, for example, regulate polypeptide, protein, or gene expression.Type: ApplicationFiled: March 15, 2018Publication date: April 30, 2020Inventors: Siddharth PATEL, Emily ROBINSON, Anna BROWN, Orn ALMARSSON, Kerry E. BENENATO, Staci SABNIS, Gaurav SAHAY, Ashwani Kumar NARAYANA
-
POLYNUCLEOTIDES ENCODING PORPHOBILINOGEN DEAMINASE FOR THE TREATMENT OF ACUTE INTERMITTENT PORPHYRIA
Publication number: 20200085916Abstract: The invention relates to mRNA therapy for the treatment of Acute Intermittent Porphyria (AIP). mRNAs for use in the invention, when administered in vivo, encode human porphobilinogen deaminase (PBGD), isoforms thereof, functional fragments thereof, and fusion proteins comprising PBGD. mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to affect efficient delivery to cells and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of PBGD expression and/or activity in subjects. mRNA therapies of the invention further decrease levels of toxic metabolites associated with deficient PBGD activity in subjects, namely porphobilinogen and aminolevulinate (PBG and ALA).Type: ApplicationFiled: May 18, 2017Publication date: March 19, 2020Inventors: Paolo Martini, Stephen Hoge, Kerry Benenato, Vladimir Presnyak, Lei Jiang, Iain McFadyen, Ellalahewage Sathyajith Kumarasinghe, Antonio Fontanellas Roma, Pedro Berraondo Lopez, Matias Antonio Avila Zaragoza, Lin Tung Guey, Staci Sabnis -
Patent number: 10556018Abstract: This disclosure provides improved lipid-based compositions, including lipid nanoparticle compositions, and methods of use thereof for delivering agents in vivo including nucleic acids and proteins. These compositions are not subject to accelerated blood clearance and they have an improved toxicity profile in vivo.Type: GrantFiled: August 10, 2017Date of Patent: February 11, 2020Inventors: Gilles Besin, Stephen Hoge, Joseph Senn, Kerry Benenato, Staci Sabnis
-
Patent number: 10519455Abstract: The invention relates to mRNA therapy for the treatment of Fabry disease. mRNAs for use in the invention, when administered in vivo, encode human the ?-galactosidase A (GLA), isoforms thereof, functional fragments thereof, and fusion proteins comprising GLA. mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to effect efficient delivery to cells and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of GLA expression and/or activity in subjects. mRNA therapies of the invention further decrease levels of toxic metabolites associated with deficient GLA activity in subjects, namely Gb3 and lyso-Gb3.Type: GrantFiled: August 23, 2018Date of Patent: December 31, 2019Assignee: ModernaTX, Inc.Inventors: Paolo Martini, Stephen G. Hoge, Kerry Benenato, Vladimir Presnyak, Iain McFadyen, Ellalahewage Sathyajith Kumarasinghe, Xuling Zhu, Lin Tung Guey, Staci Sabnis
-
Publication number: 20190382774Abstract: The invention related to polyribonucleotides comprising an open reading frame of linked nucleosides encoding a polypeptide of interest (e.g., a therapeutic polypeptide), isoforms thereof, functional fragments thereof, and fusion proteins comprising the polypeptide. In some embodiments, the open reading frame is sequence-optimized. In particular embodiments, the invention provides sequence-optimized polyribonucleotides comprising nucleotides encoding the sequence of the polypeptide of interest, or sequence having high sequence identity with those sequence optimized polyribonucleotides.Type: ApplicationFiled: May 18, 2017Publication date: December 19, 2019Inventors: Stephen G. HOGE, Kerry BENENATO, Vladimir PRESNYAK, Iain MCFADYEN, Ellalahewage Sathyajith KUMARASINGHE, Staci SABNIS, William BUTCHER